JP2003526632A5 - - Google Patents

Download PDF

Info

Publication number
JP2003526632A5
JP2003526632A5 JP2001526527A JP2001526527A JP2003526632A5 JP 2003526632 A5 JP2003526632 A5 JP 2003526632A5 JP 2001526527 A JP2001526527 A JP 2001526527A JP 2001526527 A JP2001526527 A JP 2001526527A JP 2003526632 A5 JP2003526632 A5 JP 2003526632A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001526527A
Other languages
Japanese (ja)
Other versions
JP2003526632A (ja
JP4919567B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/026500 external-priority patent/WO2001023375A2/en
Publication of JP2003526632A publication Critical patent/JP2003526632A/ja
Publication of JP2003526632A5 publication Critical patent/JP2003526632A5/ja
Application granted granted Critical
Publication of JP4919567B2 publication Critical patent/JP4919567B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001526527A 1999-09-28 2000-09-26 脈管形成抑制活性を有する置換されたピリジン類およびピリダジン類 Expired - Lifetime JP4919567B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28
US09/407,600 1999-09-28
PCT/US2000/026500 WO2001023375A2 (en) 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Publications (3)

Publication Number Publication Date
JP2003526632A JP2003526632A (ja) 2003-09-09
JP2003526632A5 true JP2003526632A5 (https=) 2005-07-28
JP4919567B2 JP4919567B2 (ja) 2012-04-18

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001526527A Expired - Lifetime JP4919567B2 (ja) 1999-09-28 2000-09-26 脈管形成抑制活性を有する置換されたピリジン類およびピリダジン類

Country Status (35)

Country Link
EP (1) EP1228063B1 (https=)
JP (1) JP4919567B2 (https=)
KR (3) KR100895571B1 (https=)
CN (3) CN100422173C (https=)
AR (3) AR025752A1 (https=)
AT (1) ATE422494T1 (https=)
AU (1) AU782820B2 (https=)
BG (1) BG65860B1 (https=)
BR (1) BRPI0014382B8 (https=)
CA (1) CA2385817C (https=)
CO (1) CO5200835A1 (https=)
CZ (1) CZ304767B6 (https=)
DE (1) DE60041548D1 (https=)
DO (1) DOP2000000070A (https=)
EE (1) EE05258B1 (https=)
ES (1) ES2320525T3 (https=)
GT (1) GT200000158A (https=)
HR (1) HRP20020308A2 (https=)
HU (1) HU230223B1 (https=)
IL (3) IL148880A0 (https=)
MA (1) MA25563A1 (https=)
MX (1) MXPA02003156A (https=)
MY (3) MY135058A (https=)
NO (1) NO20021520L (https=)
NZ (1) NZ518589A (https=)
PA (1) PA8503201A1 (https=)
PE (1) PE20010607A1 (https=)
PL (1) PL205957B1 (https=)
RS (1) RS50369B (https=)
RU (1) RU2260008C2 (https=)
SK (1) SK287417B6 (https=)
TW (1) TW593315B (https=)
UA (1) UA75053C2 (https=)
WO (1) WO2001023375A2 (https=)
ZA (1) ZA200202760B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416525A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
ATE421324T1 (de) * 2003-03-11 2009-02-15 Novartis Ag Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase
JPWO2004089412A1 (ja) * 2003-04-08 2006-07-06 三菱ウェルファーマ株式会社 特異的nad(p)hオキシダーゼ抑制剤
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-c]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
EP2010173A1 (en) * 2006-04-15 2009-01-07 Bayer HealthCare AG Compounds for treating pulmonary hypertension
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业(泰州)有限公司 一种工业化生产甲磺酸特拉替尼的方法
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA
US12421228B2 (en) * 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
WO1996005176A1 (en) * 1994-08-09 1996-02-22 Eisai Co., Ltd. Fused pyridazine compound
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ATE459616T1 (de) * 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
WO2000059509A1 (en) * 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf

Similar Documents

Publication Publication Date Title
JP2002536563A5 (https=)
JP2003510142A5 (https=)
JP2003526632A5 (https=)
JP2001191492A5 (https=)
JP2002539402A5 (https=)
JP2001309676A5 (https=)
JP2002091974A5 (https=)
JP2001308975A5 (https=)
JP2002114158A5 (https=)
JP2001310863A5 (https=)
JP2002075224A5 (https=)
JP2001332576A5 (https=)
CN3147763S (https=)
AU2000256695A8 (https=)
CN3151708S (https=)
CN3151268S (https=)
CN3151233S (https=)
CN3151191S (https=)
CN3151058S (https=)
CN3150688S (https=)
CN3150564S (https=)
CN3149245S (https=)
CN3148838S (https=)
CN3147984S (https=)
CN3151857S (https=)